Keytruda fail 'small beans' for Merck, bigger riddle for immuno-oncology scorekeepers
admin 25th July 2017 Uncategorised 0The immunotherapy mystery deepens. Merck’s Keytruda missed its goal in a head and neck cancer trial—a goal its closest rival, Bristol-Myers’ Opdivo, met last year. It’s the latest in a series of differing I-O results that highlight how much we still don’t know about these big-selling—and groundbreaking—therapies.
More: Keytruda fail 'small beans' for Merck, bigger riddle for immuno-oncology scorekeepers
Source: fierce